Sphingosine 1-phosphate receptor-1 (S1PR1) is essential for embryonic vascular development and maturation. In the adult, it is a key regulator of vascular barrier function and inflammatory processes. Its roles in tumor angiogenesis, tumor growth and metastasis are not well understood. In this report, we show that S1PR1 is expressed and active in tumor vessels. Tumor vessels that lack S1PR1 (S1pr1 ECKO) show excessive vascular sprouting and branching, decreased barrier function, and poor perfusion accompanied by loose attachment of pericytes. Compound knockout of S1pr1, 2 and 3 genes further exacerbated these phenotypes, suggesting compensatory function of endothelial S1PR2 and 3 in the absence of S1PR1. On the other hand, tumor vessels with high expression of S1PR1 (S1pr1 ECTG) show less branching, tortuosity and enhanced pericyte coverage. Larger tumors and enhanced lung metastasis were seen in S1pr1 ECKO whereas S1pr1 ECTG showed smaller tumors and reduced metastasis.
Introduction
Sphingosine-1-phosphate (S1P), a lysophospholipid found in blood and lymph, regulates cell survival, migration, immune cell trafficking, angiogenesis, and vascular barrier function. S1P binds to a family of G protein-coupled sphingosine 1-phosphate receptors 1 to 5 (S1PR1-5) which are expressed on most cells (1) . The prototypical S1PR1, which is abundantly expressed in vascular endothelial cells (EC), is required for embryonic vascular development and maturation (2, 3) . S1PR1 inhibits VEGF-induced vascular sprouting (4) by promoting interactions between VE-Cadherin and VEGFR2 that suppress VEGF signaling (5) . However, S1PR1 function is compensated by other S1PRs that are expressed in EC, albeit at lower levels. For example, S1PR2 and S1PR3, which are both capable of signaling via the Gi pathway, function redundantly as S1PR1 in embryonic vascular development (6) . Mice that lack S1PR1, 2 and 3 exhibit early embryonic lethality similar to global (7) or red blood cell-specific (8) sphingosine kinase (SPHK)-1 and -2 double knockout mice that lack circulatory S1P. These findings support the notion that coordinated signaling of VEGF-A via its receptor tyrosine kinases and plasma S1P via EC G protein-coupled S1PRs is fundamental for the development of a normal primary vascular network.
Tumor progression requires new vessel growth, a phenomenon termed as tumor angiogenesis. This is achieved by the production of angiogenic factors which activate endothelial cells from pre-existing blood vessels to undergo angiogenesis (9) . For example, angiogenic stimulators such as VEGF-A are released by tumor cells to induce angiogenesis and tumor growth (10) . Angiogenesis is also associated with spreading of tumors to metastatic sites. Tumor vessels, characterized by abnormal morphology, are highly dysfunctional in their barrier and transport properties (11) . Strategies to induce phenotypic change of tumor vessels to resemble normal vessels, termed vascular normalization, has been attempted (11) (12) (13) . Indeed, anti-VEGF antibodies induce vascular normalization in preclinical models and in the clinic, which may in part explain their efficacy in the treatment of metastatic cancer. After anti-VEGF treatment, tumor vessels show increased perfusion and efficacy of anti-tumor chemotherapies. However, preclinical studies have shown a precise time window for the efficacy of antiangiogenic therapies, as prolonged antiangiogenic treatment can lead to excessive pruning, hypoxia, activation of alternative proangiogenic pathways and the development of resistance (14) .
Even though S1P signaling via endothelial S1PRs is a central player in vascular development, the role of S1P signaling axis in tumor angiogenesis and progression is not clear.
Early studies showed that S1PR1 is expressed in tumor vessels and downregulation of its expression with 3'UTR-targeted siRNAs suppressed tumor growth (15) . However, administration of FTY720, a prodrug that is phosphorylated and binds to 4 out of 5 S1P receptors, suppressed tumor growth and metastasis in mouse models (16, 17) . Application of VEGF pathway inhibitors together with S1PR-targeted small molecules achieved better inhibition of tumor angiogenesis (18) . However, precise roles of endothelial S1PR subtypes in tumor angiogenesis, progression and metastasis has not been analyzed in genetic models. We systematically studied mouse genetic models in which S1PRs have been modified either alone or in combination, and studied tumor vascular phenotypes in syngeneic lung cancer and melanoma models. We show that endothelial S1PRs are key regulators of vascular normalization and that stimulation of this pathway enhances chemotherapeutic efficacy.
Results

S1PR1 expression and signaling regulates tumor vascular phenotype:
S1PR1 is expressed in angiogenic vessels of tumors grown subcutaneously in mice (15) . In order to determine whether S1PR1 is actively signaling in angiogenic endothelial cells, we used a mouse model referred to as S1PR1-GFP signaling mice that allows visualization of the b-arrestin recruitment to S1PR1 (19). We injected Lewis lung carcinoma cells (LLC) subcutaneously in S1PR1-GFP signaling mice and analyzed the resected tumor sections by fluorescence microscopy. GFP positivity was observed in tumor vessel like structures. GFP + cells were co-localized with PECAM-1, but not asmooth muscle actin ( Fig. 1A-D) . These data suggest that S1PR1 signaling is active in endothelial cells of angiogenic tumors.
To assess the functional role of S1PR1 in tumor angiogenesis, we used a mouse model in which S1pr1 is deleted specifically in endothelial cells by tamoxifen-activated
Cre recombinase (S1pr1 flox/flox Cdh5 Cre-ER T2 ), which is referred to as S1pr1 ECKO (4, (20) (21) (22) . Tumors grown in S1pr1 ECKO mice were almost 2 times bigger than the tumors grown in control mice (Fig. 1E ). Water content in both the S1pr1 ECKO and control mice was similar (Fig. 1F) , suggesting that increased vascular leak in the tumor is not the cause of the increase in tumor size. Histological analysis did not reveal marked changes in matrix accumulation. These data suggest that increased tumor cell proliferation and/or recruitment of host-derived cells may be the reason for increased tumor size.
To determine the functional role of S1PR1 in tumor angiogenesis, vascular density and morphology were assessed in tumor sections and analyzed by light and confocal fluorescence microscopy followed by quantitative image analysis ( Fig. 1G-I ). Tumor vessels in S1pr1 ECKO mice show higher vascular density, excessive sprouting and branching ( Fig. 1G-K) . These data indicate that S1PR1 is present and active in tumor vascular endothelial cells and suppresses hypersprouting of intratumoral vessels.
Loss of S1PR1 expression in endothelial cells impairs mural cell coverage of tumor vessels:
During embryonic development, S1PR1 expression on endothelial cells is important for vascular stabilization and mural cell recruitment (3). Sections from tumors grown in S1pr1 ECKO and control animals were assessed for mural cell coverage.
Immunohistochemical staining with alpha smooth muscle actin (a-SMA) antibody show that tumor vessels from S1pr1 ECKO are deficient in smooth muscle actin positive cell coverage ( Fig. 2A-C) . On the other hand, NG2 + pericytes were similar in number in both WT and S1pr1 ECKO tumor vessels (Fig. 2D,E) . However, pericyte attachment to the endothelial cells in the tumor vessels from S1pr1 ECKO mice appeared loose, with pericytes weakly adhered to the endothelial cell layer, which is in sharp contrast to the WT counterparts. The lack of a-SMA+ mural cell coverage, and loose association of NG2 + pericytes, may in part explain the altered vascular morphology seen in S1pr1 ECKO tumor vessels.
Tumors in S1pr1 ECKO mice show increased vascular permeability and metastatic
potential:
Since tumor vessels from S1pr1 ECKO mice showed deficient maturation, we characterized their vascular barrier properties. We performed intravenous injection of high Since vascular leakage could lead to tissue perfusion defects and hypoxia (23),
we used the oxygen-sensitive probe termed as hypoxyprobe-1 to determine the hypoxia status of tumors in WT and S1pr1 ECKO mice (24). As shown in Fig. 3E and F, hypoxic zones of S1pr1 ECKO tumors trended towards an increase even though the difference was statistically not significant, suggesting a minor change in tumor oxygenation.
Intravenous tail vein injection of B16F10 melanoma cells into WT and S1pr1 ECKO mice, which results in lung metastasis, showed markedly increased metastatic nodules in the lungs of the mice that lack endothelial S1PR1 (Fig. 3G,H) , suggesting that aforementioned vascular defects contributed to lung colonization of circulating tumor cells and metastasis.
Taken together, these data show that S1PR1 expressed on endothelial cells regulates tumor angiogenesis, vessel maturation, vascular permeability, and tumor perfusion thus influencing primary tumor growth and metastatic potential.
Redundant functions of S1PR2 and 3 in the regulation of the tumor vascular phenotypes, tumor growth and metastasis:
Endothelial cells express S1PR2 and S1PR3 in addition to S1PR1 (25). While S1PR1 and S1PR2 induce opposing cellular effects, for example, in barrier function, S1PR2 can activate redundant signaling pathways in the absence of S1PR1 (26-28). In addition, both S1PR2 and S1PR3 are capable of signaling redundantly as S1PR1; for example, via the Gi pathway (29-32). The roles of these receptors in tumor angiogenesis has not been examined.
We recently developed a conditional mutant allele for S1pr2 and developed a mouse model for S1pr2 ECKO using the tamoxifen-inducible Cdh5-Cre driver (33). Using this mouse model with LLC tumors, angiogenesis tumor vascular phenotypes were analyzed. As shown in Fig. 4A , tumors grown in S1pr2 ECKO mice were significantly smaller than those in the WT counterparts. Tumor vasculature showed no significant changes in permeability to intravenously injected 70kD fluorescent dextran (Fig. 4B ).
However, increased pericyte coverage was seen (Fig. 4C) . Moreover, intravenously injected B16 melanoma cells showed decreased metastatic potential in the lungs of S1pr2 ECKO (Fig. 4D) . These results reveal the opposing functions of S1PR1 and S1PR2 in tumor vascular phenotype regulation.
When compound S1pr1 S1pr2 ECKO mice were analyzed, subcutaneous LLC tumors were similar in size, and NG2 + and a-SMA + mural cell recruitment to tumor vessels was not different from the control counterparts (Fig. 4E ). Tumor vascular phenotype showed modest hypersprouting ( Fig. 4F-G) , suggesting that the effects of S1pr1 ECKO were neutralized by the lack of S1PR2, which mediates opposite endothelial phenotypic effects. Additionally, the percent of a-SMA + , CD31 + and NG2 + , CD31 + double signal were similar in both S1pr1 S1pr2 WT and ECKO mice ( Fig.4F-G) .
We next examined the redundant role of S1PR3 in tumor angiogenesis. When S1pr3 -/-mice (6) were compared with compound S1pr1 ECKO S1pr3 -/-mice, tumor growth, vascular density and the recruitment of a-SMA + and NG2 + mural cells to tumor vessels largely resembled that of S1pr1 ECKO mice ( Fig. 5A -E). However, compound triple KO of S1pr1 and S1pr2 ECKO in S1pr3 -/-background showed marked increase in tumor growth, vascular hypersprouting and mural cell disengagement phenotypes ( Fig.   5F ,G). These data suggest that S1PR3 functions are redundant to S1PR1 in suppressing endothelial hypersprouting as well as properties of highly abnormal vascular phenotypes.
Together, these findings support the redundant functions of S1PR2 and S1PR3, which compensate the function of attenuated S1PR1.
Overexpression of S1PR1 in endothelial cells promotes normalization of tumor vessels and enhances chemotherapeutic efficacy:
Due to the prominent role of endothelial S1PR1 in tumor vasculature, growth and metastatic potential, we used the inducible S1PR1 endothelial-specific transgenic mice Intravenously injected B16F10 melanoma cells also formed fewer number of metastatic nodules in the lung (Fig. 7H,I ). Together, these data suggest that increased S1PR1 expression in endothelial cells promotes tumor vascular normalization and suppresses metastatic potential.
Since normalization of tumor vessels were shown to enhance anti-tumor therapies (11-14, 34), we injected anti-tumor chemotherapy drug doxorubicin to tumor bearing WT and S1PR1 ECTG mice every other day, starting at day 8 post injection of the LLC. As expected, doxorubicin treatment reduced the growth of the tumors in both cohorts of mice.
However, in the S1PR1 ECTG mice, doxorubicin treatment was more effective in reducing tumor growth (Fig. 7J ). These data suggest that S1pr1-induced tumor vascular normalization enhances the chemotherapeutic efficiency of doxorubicin.
Discussion
S1P signaling axis via the endothelial S1PRs represent a major regulatory system for vascular maturation during development (6) . Balanced signaling between angiogenic growth factors such as VEGF that signals via receptor tyrosine kinases and S1PRs which are GPCRs is essential for normal vascular development (35). In the adult, endothelial S1PR signaling regulates vascular barrier function, tone and inflammatory processes.
Since tumor angiogenesis occurs postnatally, we studied the role of endothelial cell S1PR
signaling axis in mouse models of tumor angiogenesis, progression and metastasis.
A principle finding of our work is that the level of S1PR expression in the tumor endothelium determines key aspects of the tumor vascular phenotype. These include endothelial sprouting, branching phenotypes and the barrier function. Lack of endothelial S1PR1 promoted excessive vascular leak, as well as markedly increased vascular sprouting and branching. We predict that attenuated S1PR1 function in the tumor endothelium would lead to decreased access of blood borne cells and substances to the tumor parenchyma. Opposite phenotypes were seen by overexpression of endothelial S1PR1. Our results suggest that S1PR1-regulated events in the newly-formed tumor vessels are important in determining their normalization status.
We also show that attenuated endothelial S1PR1 function led to increased tumor growth whereas S1PR1 overexpression led to smaller tumors. Intratumoral fluid accumulation is unable to account for the changes in tumor size. Either tumor cell proliferation and/or stromal hematopoietic cell infiltration could be affected by the signaling of endothelial S1PRs. We speculate that elaboration of angiocrine functions of tumor endothelial cells that influence tumor cells per se and/or cells of the tumor microenvironment are involved.
In addition to tumor vascular normalization and progression, we show that the signaling of endothelial S1PR1 influences the ability of circulating tumor cells to establish metastatic colonies in lungs. Since defective endothelial junctions leading to decreased barrier properties of the tumor vessels are controlled by this receptor, we suggest that this function of S1P signaling axis regulates metastatic potential of circulating tumor cells.
However, modulation of immune cell infiltration into the tumor microenvironment and the elaboration of anti-tumor immunity, in particular by NK and CD8+ T cells may be involved.
In fact, it was recently shown that loss of the S1P transporter Spns2, which is highly expressed in the endothelium, suppressed metastatic potential of circulating tumor cells in mouse models (36).
Using the genetic loss of function models of S1PR2 and S1PR3, either alone or in combination with S1PR1, we show that these two S1PRs compensate for the loss of S1PR1 in tumor vascular endothelium. This finding may be useful in the design of therapeutic approaches to enhance tumor vascular normalization.
The clinical relevance of our study is underscored by the finding that doxorubicininduced tumor growth suppression is more effective in endothelial S1PR1 transgenic mice which show enhanced S1P signaling in the tumor vasculature.
In summary, our study shows that endothelial S1PR signaling is an important factor in tumor vascular phenotype that influences tumor progression, metastasis and chemotherapeutic efficacy. Strategies to enhance S1PR1 function in the tumor vasculature may potentiate the efficacy of cytotoxic and targeted anti-cancer therapies.
Materials and Methods
Mouse strains
Mice were housed in a temperature-controlled facility with a 12-h light/dark cycle, specific pathogen-free, in individual ventilated cages and provided food and water ad libitum. All animal experiments were approved by the Boston Children's Hospital and Weill Cornell
Medicine Institutional Animal Care and Use Committees. EC-specific S1pr1 knockout
; S1pr1 ECKO) were generated as described (4, (20) (21) (22) .
EC-specific S1pr2 knockout mice (S1pr2 f/f Cdh5-Cre-ER
T2
; S1pr2 ECKO) were generated as follows. To create S1pr2 conditional knockout targeting construct, loxP sites were Mice carrying the primary targeted alleles were crossed to germline Flp mice to excise the frt-PGK-Neo-frt cassette. They were then crossed to Cdh5-Cre-ER T2 mice to generate S1pr2 ECKO mice. EC-specific S1pr1-S1pr2 double knockout mice were generated by crossing S1pr1 ECKO with S1pr2 ECKO mice. EC-specific S1pr1-S1pr2 double knockout mice in the S1pr3 -/-background were generated by crossing the S1pr1 ECKO -S1pr2
ECKO mice with S1pr3 -/-mice (6). S1pr1 f/stop/f was generated as described (4, 20) by knocking in the transgene into embryonic stem cells (ESCs) and crossed to Cdh5-Cre-ER T2 mice. Gene deletion or overexpression by the cre recombinase was achieved by intraperitoneal injection of tamoxifen (Sigma-Aldrich) (150 µg/gram of body weight/day) at 6 weeks of age for five consecutive days, and mice were allowed to recover for a week before being used for experiments. Littermates without the Cdh5-Cre-ER T2 gene were treated with tamoxifen in the same way and used as controls. S1P1-GFP reporter mice have been previously described (19). Briefly, mice expressing a transcriptional unit consisting of the S1PR1 carboxy terminus fused to tetracycline transcriptional activator (tTA) and ß-arrestin fused to tobacco etch virus (TEV) protease knocked in to the endogenous S1pr1 locus were crossed with mice containing a histone-GFP reporter gene under the control of a tTA-responsive promoter. Mice expressing one allele of both transgenes were considered S1PR1 GFP signaling mice. Littermates expressing only the GFP allele without the S1P1 knock-in were considered controls (19). All genotyping was done by PCR using ear punch biopsies.
Cell lines
Lewis lung carcinoma cells (LLC, ATCC-CRL-1642) used for subcutaneous injection and 
Quantitation of tumor hypoxia
To determine the hypoxic area of the tumor vasculature, tumor bearing mice were injected via tail vein with the oxygen-sensitive compound Hypoxyprobe-1 (pimonidazole hydrochloride, Hypoxyprobe, Inc) at a dosage of 60 mg/kg body weight as previously described (4). After 90 min, mice were euthanized and perfused with 10 mL of PBS. The tumors were harvested, fixed in 4% PFA, sectioned, permeabilized, and stained with an anti-Hypoxyprobe-1 antibody and CD31 (BD Pharmigen). Image processing and quantification was performed using Adobe Photoshop, ImageJ, or Fiji software (National Institutes of Health). Hypoxyprobe-1 positive immunofluorescent signals were subjected to threshold processing and areas occupied by their signal were quantified by using the Fiji Software, and normalized to the total area of the tumor.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software v. Whitney test comparing control S1pr1 WT and S1pr1 ECKO mice. ns, nonsignificant, P* ≤ 0.0332, P** ≤ 0.0021, P*** ≤ 0.0002, P****≤ 0.0001. foci is expressed as mean ± SD. P values were determined by two-tailed unpaired t test with Welch'comparing control and S1pr2 ECKO mice. P*** ≤ 0.0002.
(E) Whole tumor weight of subcutaneous LLC tumors grown in S1pr1, S1pr2 WT and ECKO mice. n=3 independent experiments containing 3 mice per group, expressed as a mean of 2 tumors per animal ± SD. P values were determined by two-tailed unpaired
Mann-Whitney test comparing S1pr1, S1pr2 WT and ECKO mice. ns, nonsignificant.
(F) 35µm tumor sections from S1pr1, S1pr2 WT and ECKO mice were stained with CD31
and a-SMA or pericyte marker NG2 and show vascular morphology and mural cell coverage. Quantification from confocal images (n=5-7 per group) of total a-SMA and NG2
positive signal per CD31 positive signal are expressed as mean ± SD. P values were determined by two-tailed unpaired Mann-Whitney test comparing control and S1pr2 ECKO mice. ns, nonsignificant. Mann-Whitney test comparing S1pr1 WT, S1pr3 -/-and S1pr1 ECKO, S1pr3 -/-mice. ns, nonsignificant, P* ≤ 0.0332 (E) Immunofluorescence (IF) of 35 µm sections of tumor grown in S1pr1 WT, S1pr3 -/-and S1pr1 ECKO, S1pr3 -/-mice and stained with S1PR1, CD31, NG2 and a-SMA antibodies, shows extensive deletion of S1PR1 signal in endothelial cells by confocal microscopy, vascular morphology and mural cell coverage.
(F) Whole tumor weight of subcutaneous LLC tumors grown in S1pr1 WT, S1pr2 WT,
S1pr3
-/-and S1pr1 ECKO, S1pr2 ECKO, S1pr3 -/-mice. n=2 independent experiments containing 2 or 3 mice per group, expressed as a mean of 2 tumors per animal ± SD. P values were determined by two-tailed unpaired Mann-Whitney test comparing S1pr3
and S1pr1 ECKO, S1pr2 ECKO, S1pr3 -/-mice. P ≤ 0.05 (G) 35µm tumor sections stained with CD31, a-SMA and NG2 antibodies show vascular morphology and mural cell coverage. 
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